RP2 plus standard treatment for advanced liver or bile cancers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial studies whether RP2, added to standard second-line treatment, can improve outcomes for people with advanced liver cancer or bile duct/gallbladder cancer. It may help by training the immune system to better attack the cancer after the cancer has already grown despite prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult age 18 or older
- You have advanced, not fully removable cancer (liver cancer or bile duct/gallbladder cancer, depending on the study group)
- For liver cancer: your cancer got worse after prior first treatment that included an anti–PD-1 or anti–PD-L1 drug
- Your liver is working well enough for treatment (Child-Pugh A and blood test limits)
- You must be able and willing to provide a tumor biopsy sample (new or stored) within 90 days before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
This trial is testing a new approach for people with advanced liver cancer: giving a second-line drug therapy along with targeted radiation (SBRT) to the spots that are growing. The goal is to control the cancer better and possibly help you live longer.
This Phase 2 trial studies whether adding a cancer vaccine (to help the immune system recognize your tumor) to two medicines—atezolizumab and bevacizumab—can better control unresectable or advanced liver cancer. It’s for people who haven’t had prior whole-body (systemic) cancer treatment.
This trial tests a new combination of immunotherapy drugs (JS207 and JS007) against the current standard treatment (toripalimab plus bevacizumab) for advanced liver cancer that hasn't been treated before. The goal is to see if the new combo works better and shrinks tumors or delays growth.
This Phase 2 trial tests three medicines together (durvalumab, tremelimumab, and bevacizumab) to treat non-surgical (non-resectable) liver cancer. It may help shrink tumors and slow disease progression by boosting the immune system and blocking tumor blood supply.
This clinical trial tests a new treatment called RP2 (a virus that attacks cancer cells) combined with nivolumab (an immunotherapy drug) for people with metastatic uveal melanoma who have never had immunotherapy before. It aims to see if this combination can shrink tumors and improve outcomes.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.